Prediction of tumor control in 90Y radioembolization by logit models with PET/CT based dose metrics.
The aim of this work was to develop models for tumor control probability (TCP) in radioembolization with 90Y PET/CT- derived radiobiologic dose metrics. Methods: Patients with primary liver cancer or liver metastases who underwent radioembolization with glass microspheres were imaged with 90Y PET/CT for voxel-level dosimetry to determine lesion absorbed dose (AD) metrics, biological effective dose (BED) metrics, equivalent uniform dose (EUD) and EUBED for 28 treatments (89 lesions). The lesion dose - shrinkage correlation was assessed based on RECIST, and when available, mRECIST criteria at first follow-up. For a subset with mRECIST, logit regression TCP models were fit via maximum likelihood to relate lesion level binary response to the dose metrics. As an exploratory analysis, the non-tumoral liver dose - toxicity was also evaluated. Results: Lesion dose - shrinkage analysis showed no significant differences between model parameters for primary and metastatic sub-groups and also showed that correlation coefficients were superior with mRECIST. Therefore, subsequent TCP analysis was performed for the combined group and using mRECIST only. The overall lesion-level mRECIST response rate was 57%. The AD and BED metrics yielding 50% TCP were 292 and 441 Gy, respectively. All of the dose metrics considered for TCP modeling, including mean AD, were significantly associated with the probability of response with high area under the curve (AUC) values (0.87 to 0.90, p<0.0001) and high sensitivity (>0.75) and specificity (>0.83) values calculated using a threshold corresponding to 50% TCP. Because non-uniform absorbed dose deposition by microspheres at the microscopic scale cannot be determined by PET, radiosensitivity values extracted here by fitting models to clinical response data, were substantially lower than reported for in-vitro cell cultures as well as for external beam radiotherapy clinical studies. There was no correlation between non-tumoral liver AD and toxicity measures. Conclusion: Despite the heterogenous patient cohort, logistic regression TCP models showed a strong association between various dose metrics and the probability of response. The performance of mean AD was comparable to that of radiobiologic dose metrics that involve more complex calculations. These results demonstrate the importance of considering TCP in treatment planning for radioembolization.